Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

November 16, 2026 updated by: ADARx Pharmaceuticals, Inc.

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

85

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Sydney, Australia, NSW 2139
        • Recruiting
        • ADARx Clinical Site
      • Woolloongabba, Australia, QLD 4102
        • Recruiting
        • ADARx Clinical Site
    • New South Wales
      • Liverpool, New South Wales, Australia, 2170
        • Recruiting
        • ADARx Clinical Site
      • Wollongong, New South Wales, Australia, 2500
        • Recruiting
        • ADARx Clinical Site
      • Hong Kong, Hong Kong, 2500
        • Recruiting
        • ADARx Clinical Site
      • Shatin, Hong Kong
        • Recruiting
        • ADARx Clinical Site
      • Bergamo, Italy, 24020
        • Recruiting
        • ADARx Clinical Site
      • Bologna, Italy, 40138
        • Recruiting
        • ADARx Clinical Site
      • Pavia, Italy, 27100
        • Recruiting
        • ADARx Clinical Site
      • Cheonan, South Korea, 31151
        • Recruiting
        • ADARx Clinical Site
      • Daegu, South Korea, 42601
        • Recruiting
        • ADARx Clinical Site
      • Gyeonggi-do, South Korea, 05278
        • Recruiting
        • ADARx Clinical Site
      • Seoul, South Korea, 03722
        • Recruiting
        • ADARx Clinical Site
      • Seoul, South Korea, 02841
        • Recruiting
        • ADARx Clinical Site
      • Seoul, South Korea, 03080
        • Recruiting
        • ADARx Clinical Site
      • Seoul, South Korea, 05278
        • Recruiting
        • ADARx Clinical Site
    • Gangwon-do
      • Wŏnju, Gangwon-do, South Korea, 26426
        • Recruiting
        • ADARx Clinical Site
    • Gurogu
      • Gyeonggi-do, Gurogu, South Korea, 16499
        • Recruiting
        • ADARx Clinical Site
      • Seoul, Gurogu, South Korea, 08308
        • Recruiting
        • ADARx Clinical Site
      • Barcelona, Spain, 08035
        • Recruiting
        • ADARx Clinical Site
      • Madrid, Spain, 28041
        • Recruiting
        • ADARx Clinical Site
      • Madrid, Spain, 28040
        • Recruiting
        • ADARx Clinical Site
      • Seville, Spain, 41009
        • Recruiting
        • ADARx Clinical Site
      • Kaohsiung City, Taiwan, 833401
        • Not yet recruiting
        • ADARx Clinical Site
      • New Taipei City, Taiwan, 110
        • Recruiting
        • ADARx Clinical Site
      • Newcastle upon Tyne, United Kingdom, UK, NE7 7DN
        • Recruiting
        • ADARx Clinical Site
    • BC
      • Leicester, BC, United Kingdom, LE5 4PW
        • Recruiting
        • ADARx Clinical Site
    • Florida
      • Doral, Florida, United States, 33122
        • Withdrawn
        • ADARx Clinical Site
      • Miami, Florida, United States, 33127
        • Recruiting
        • ADARx Clinical Site
      • Pembroke Pines, Florida, United States, 33029
        • Withdrawn
        • ADARx Clinical Site
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Recruiting
        • ADARx Clinical Site
    • Louisiana
      • Shreveport, Louisiana, United States, 71101
        • Withdrawn
        • ADARx Clinical Site
    • Michigan
      • Shelby, Michigan, United States, 48315
        • Recruiting
        • ADARx Clinical Site
    • New York
      • Great Neck, New York, United States, 11021
        • Recruiting
        • ADARx Clinical Site
    • Ohio
      • Columbus, Ohio, United States, 43210
        • Recruiting
        • ADARx Clinical Site
    • South Dakota
      • Dakota Dunes, South Dakota, United States, 57049
        • Recruiting
        • ADARx Clinical Site
    • Texas
      • Dallas, Texas, United States, 75230
        • Withdrawn
        • ADARx Clinical Site
      • Houston, Texas, United States, 77027
        • Recruiting
        • ADARx Clinical Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Mean eGFR greater than or equal to 30 mL/min/1.73m2
  • Clinical evidence of active kidney disease
  • Treated with supportive care including an ACE inhibitor or ARB if applicable
  • Willing to receive required vaccinations
  • Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy

Exclusion Criteria:

  • Hereditary or acquired complement deficiency
  • Kidney transplant or renal replacement therapy
  • History of solid organ transplant
  • Other kidney disease
  • History of recurrent invasive infections
  • Received complement inhibitor treatments
  • Active systemic viral, bacterial, or fungal infection
  • Abnormal liver function

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ADX-038 Dose Level 1 - IgAN

siRNA duplex oligonucleotide

Experimental: ADX-038 Dose Level 2 - IgAN

siRNA duplex oligonucleotide

Experimental: ADX-038 Dose Level 1 - C3G or IC-MPGN

siRNA duplex oligonucleotide

Experimental: ADX-038 Dose Level 2 - IgAN, C3G, or IC-MPGN

siRNA duplex oligonucleotide

Experimental: ADX-038 Dose Level 3 - IgAN, C3G, or IC-MPGN

siRNA duplex oligonucleotide

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the safety and tolerability of ADX-038
Time Frame: Length of study - From Day 1 through Month 24

Incidence and severity of TEAEs

Length of study - From Day 1 through Month 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
24-hour Urine
Time Frame: Month 12

Change from baseline to Month 12 in urine protein-creatinine ratio, measured using 24-hour urine

Month 12
Spot Urine
Time Frame: Month 12

Change from baseline to Month 12 in urine protein-creatinine ratio, measured using spot urine.

Month 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Arezoo Mirad, MD, ADARx Pharmaceuticals, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 28, 2025

Primary Completion (Estimated)

April 30, 2030

Study Completion (Estimated)

July 31, 2030

Study Registration Dates

First Submitted

May 22, 2025

First Submitted That Met QC Criteria

May 22, 2025

First Posted (Actual)

May 25, 2025

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ADX-038-201

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.